COMy 2020 | The impact of CHIP expression on multiple myeloma treatment
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses stem cell mutations and their implications for treating multiple myeloma. With age, many people get stem cell mutations such as clonal hematopoiesis of indeterminate potential (CHIP), however, in multiple myeloma, they could have larger implications. One study investigated CHIP mutations in stem cells collected during transplant therapy of 600 patients. It was noted that CHIP was elevated in myeloma patients and survival was worse which is consistent with other research. Patients that received lenalidomide or thalidomide, surprisingly, did not show a difference in CHIP expression. It is possible that specific mutations, such as P53, could have bigger ramifications. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
